FY2030 EPS Forecast for Palisade Bio Decreased by Analyst

Posted by George Bondi on Aug 18th, 2026

Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Brookline Capital Markets cut their FY2030 earnings estimates for Palisade Bio in a research report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings of $0.39 per share for the year, down from their previous forecast of $0.41. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share.

Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.50 million.

Several other equities research analysts also recently weighed in on the company. Oppenheimer initiated coverage on Palisade Bio in a research report on Thursday, July 23rd. They issued an “outperform” rating and a $8.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Palisade Bio in a report on Tuesday, June 30th. Weiss Ratings lowered Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $9.00.

View Our Latest Research Report on Palisade Bio

Palisade Bio Trading Up 0.5%

Shares of NASDAQ PALI opened at $2.15 on Monday. The stock has a fifty day moving average price of $1.96 and a 200 day moving average price of $1.92. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.86. The company has a market cap of $374.68 million, a P/E ratio of -2.13 and a beta of 1.52.

Insiders Place Their Bets

In other news, insider Mitchell Lawrence Jones sold 51,880 shares of Palisade Bio stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the sale, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. The trade was a 35.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the sale, the chief executive officer directly owned 217,555 shares in the company, valued at approximately $450,338.85. The trade was a 40.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have bought 125,000 shares of company stock worth $250,100 in the last quarter. 0.07% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PALI. Octagon Capital Advisors LP increased its holdings in Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock worth $17,984,000 after purchasing an additional 708,419 shares during the last quarter. Commodore Capital LP purchased a new position in shares of Palisade Bio during the 4th quarter valued at approximately $26,896,000. Artia Global Partners LP acquired a new stake in shares of Palisade Bio during the fourth quarter worth approximately $4,682,000. Creek Drive Management Group LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth approximately $723,000. Finally, Orbimed Advisors LLC grew its position in shares of Palisade Bio by 24.7% during the first quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock worth $4,083,000 after buying an additional 461,580 shares in the last quarter. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.